Abstract
Experimental studies on immunoglobulin superfamily (IgSF) member EWI2 reveal that it suppresses a variety of solid malignant tumors including brain, lung, skin, and prostate cancers in animal models and inhibits tumor cell movement and growth in vitro. While EWI2 appears to support myeloid leukemia in mouse models and maintain leukemia stem cells. Bioinformatics analyses suggest that EWI2 gene expression is downregulated in glioblastoma but upregulated in melanoma, pancreatic cancer, and liver cancer. The mechanism of action for EWI2 is linked to its inhibition of growth factor receptors and cell adhesion proteins through its associated tetraspanin-enriched membrane domains (TEMDs), by altering the cell surface clustering and endolysosome trafficking/turnover of these transmembrane proteins. Recent studies also show that EWI2 modulates the nuclear translocation of ERK and TFEB to change the activities of these gene expression regulators. For EWI2 relatives including FPRP, IgSF3, and CD101, although their roles in malignant diseases are not fully clear and remain to be determined experimentally, FPRP and IgSF3 likely promote the progression of solid malignant tumors while CD101 seems to modulate immune cells of tumor microenvironment. Distinctive from other tumor regulators, the impacts of EWI subfamily members on solid malignant tumors are likely to be context dependent. In other words, the effect of a given EWI subfamily member on a tumor probably depends on the molecular network and composition of TEMDs in that tumor. Collectively, EWI2 and its relatives are emerged as important regulators of malignant diseases with promising potentials to become anti-cancer therapeutics and cancer therapy targets.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The data that support the findings of this study are openly available from STRING database at https://string-db.org/, reference number 35, and TCGA database at https://www.cancer.gov/structural-genomics/tcga.
References
Charrin S, Le Naour F, Labas V, Billard M, Le Caer JP, Emile JF, et al. EWI-2 is a new component of the tetraspanin web in hepatocytes and lymphoid cells. Biochem J. 2003;373:409–21.
Clark KL, Zeng Z, Langford AL, Bowen SM, Todd SC. PGRL is a major CD81-associated protein on lymphocytes and distinguishes a new family of cell surface proteins. J Immunol. 2001;167:5115–21.
Stipp CS, Kolesnikova TV, Hemler ME. EWI-2 is a major CD9 and CD81 partner and member of a novel Ig protein subfamily. J Biol Chem. 2001;276:40545–54.
Zhang XA, Lane WS, Charrin S, Rubinstein E, Liu L. EWI2/PGRL associates with the metastasis suppressor KAI1/CD82 and inhibits the migration of prostate cancer cells. Cancer Res. 2003;63:2665–74.
He B, Zhang YH, Richardson MM, Zhang JS, Rubinstein E, Zhang XA. Differential functions of phospholipid binding and palmitoylation of tumour suppressor EWI2/PGRL. Biochem J. 2011;437:399–411.
Kolesnikova TV, Stipp CS, Rao RM, Lane WS, Luscinskas FW, Hemler ME. EWI-2 modulates lymphocyte integrin alpha4beta1 functions. Blood. 2004;103:3013–9.
Yang XH, Kovalenko OV, Kolesnikova TV, Andzelm MM, Rubinstein E, Strominger JL, et al. Contrasting effects of EWI proteins, integrins, and protein palmitoylation on cell surface CD9 organization. J Biol Chem. 2006;281:12976–85.
Charrin S, Jouannet S, Boucheix C, Rubinstein E. Tetraspanins at a glance. J Cell Sci. 2014;127:3641–8.
Richardson MM, Jennings LK, Zhang XA. Tetraspanins and tumor progression. Clin Exp Metastasis. 2011;28:261–70.
van Deventer SJ, Dunlock VE, van Spriel AB. Molecular interactions shaping the tetraspanin web. Biochem Soc Trans. 2017;45:741–50.
Yanez-Mo M, Barreiro O, Gordon-Alonso M, Sala-Valdes M, Sanchez-Madrid F. Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. Trends Cell Biol. 2009;19:434–46.
Hemler ME. Tetraspanin proteins promote multiple cancer stages. Nat Rev Cancer. 2014;14:49–60.
Vences-Catalan F, Levy S. Immune Targeting of Tetraspanins Involved in Cell Invasion and Metastasis. Front Immunol. 2018;9:1277.
Wang HX, Sharma C, Knoblich K, Granter SR, Hemler ME. EWI-2 negatively regulates TGF-beta signaling leading to altered melanoma growth and metastasis. Cell Res. 2015;25:370–85.
Wang J, Wren JD, Ding Y, Chen J, Mittal N, Xu C, et al. EWI2 promotes endolysosome-mediated turnover of growth factor receptors and integrins to suppress lung cancer. Cancer Lett. 2022;536:215641.
Fu C, Wang J, Pallikkuth S, Ding Y, Chen J, Wren JD, et al. EWI2 prevents EGFR from clustering and endocytosis to reduce tumor cell movement and proliferation. Cell Mol Life Sci. 2022;79:389.
Feng J, Huang C, Wren JD, Wang DW, Yan J, Zhang J, et al. Tetraspanin CD82: a suppressor of solid tumors and a modulator of membrane heterogeneity. Cancer Metastasis Rev. 2015;34:619–33.
Fu C, Zhang Q, Wang A, Yang S, Jiang Y, Bai L, et al. EWI-2 controls nucleocytoplasmic shuttling of EGFR signaling molecules and miRNA sorting in exosomes to inhibit prostate cancer cell metastasis. Mol Oncol. 2021;15:1543–65.
Levina E, Ji H, Chen M, Baig M, Oliver D, Ohouo P, et al. Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells. Oncotarget. 2015;6:13088–104.
Kolesnikova TV, Kazarov AR, Lemieux ME, Lafleur MA, Kesari S, Kung AL, et al. Glioblastoma inhibition by cell surface immunoglobulin protein EWI-2, in vitro and in vivo. Neoplasia. 2009;11:77–86.
Huang C, Fu C, Wren JD, Wang X, Zhang F, Zhang YH, et al. Tetraspanin-enriched microdomains regulate digitation junctions. Cell Mol Life Sci. 2018;75:3423–39.
Sala-Valdes M, Ursa A, Charrin S, Rubinstein E, Hemler ME, Sanchez-Madrid F, et al. EWI-2 and EWI-F link the tetraspanin web to the actin cytoskeleton through their direct association with ezrin-radixin-moesin proteins. J Biol Chem. 2006;281:19665–75.
Stipp CS, Kolesnikova TV, Hemler ME. EWI-2 regulates alpha3beta1 integrin-dependent cell functions on laminin-5. J Cell Biol. 2003;163:1167–77.
Gordon-Alonso M, Sala-Valdes M, Rocha-Perugini V, Perez-Hernandez D, Lopez-Martin S, Ursa A, et al. EWI-2 association with alpha-actinin regulates T cell immune synapses and HIV viral infection. J Immunol. 2012;189:689–700.
Liang Y, Eng WS, Colquhoun DR, Dinglasan RR, Graham DR, Mahal LK. Complex N-linked glycans serve as a determinant for exosome/microvesicle cargo recruitment. J Biol Chem. 2014;289:32526–37.
Jimbo K, Nakajima-Takagi Y, Ito T, Koide S, Nannya Y, Iwama A, et al. Immunoglobulin superfamily member 8 maintains myeloid leukemia stem cells through inhibition of beta-catenin degradation. Leukemia. 2022;36:1550–62.
Beckwith KA, Byrd JC, Muthusamy N. Tetraspanins as therapeutic targets in hematological malignancy: a concise review. Front Physiol. 2015;6:91.
Suwatthanarak T, Tanaka M, Miyamoto Y, Miyado K, Okochi M. Inhibition of cancer-cell migration by tetraspanin CD9-binding peptide. Chem Commun (Camb). 2021;57:4906–9.
Claas C, Wahl J, Orlicky DJ, Karaduman H, Schnolzer M, Kempf T, et al. The tetraspanin D6.1A and its molecular partners on rat carcinoma cells. Biochem J. 2005;389:99–110.
Colin S, Guilmain W, Creoff E, Schneider C, Steverlynck C, Bongaerts M, et al. A truncated form of CD9-partner 1 (CD9P-1), GS-168AT2, potently inhibits in vivo tumour-induced angiogenesis and tumour growth. Br J Cancer. 2011;105:1002–11.
Aguila B, Morris AB, Spina R, Bar E, Schraner J, Vinkler R, et al. The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme. Cancer Lett. 2019;462:33–42.
Chen S, Sun Y, Jin Z, Jing X. Functional and biochemical studies of CD9 in fibrosarcoma cell line. Mol Cell Biochem. 2011;350:89–99.
Sheng P, Zhu H, Zhang W, Xu Y, Peng W, Sun J, et al. The immunoglobulin superfamily member 3 (IGSF3) promotes hepatocellular carcinoma progression through activation of the NF-kappaB pathway. Ann Transl Med. 2020;8:378.
Erfani S, Hua H, Pan Y, Zhou BP, Yang XH. The context-dependent impact of integrin-associated CD151 and other tetraspanins on cancer development and progression: A class of versatile mediators of cellular function and signaling, tumorigenesis and metastasis. Cancers. 2021;13:2005.
Ramovs V, Te Molder L, Sonnenberg A. The opposing roles of laminin-binding integrins in cancer. Matrix Biol: J Int Soc Matrix Biol. 2017;57-58:213–43.
Liu Y, Yao R, Shi Y, Liu Y, Liu H, Liu J, et al. Identification of CD101 in Glioma: A novel prognostic indicator expressed on M2 macrophages. Front Immunol. 2022;13:845223.
Zhou J, Wang W, Liang Z, Ni B, He W, Wang D. Clinical significance of CD38 and CD101 expression in PD-1(+)CD8(+) T cells in patients with epithelial ovarian cancer. Oncol Lett. 2020;20:724–32.
Bobrowicz M, Kubacz M, Slusarczyk A, Winiarska M. CD37 in B cell derived tumors-more than just a docking point for monoclonal antibodies. Int J Mol Sci. 2020;21:9531.
de Winde CM, Elfrink S, van Spriel AB. Novel insights into membrane targeting of B cell lymphoma. Trends cancer. 2017;3:442–53.
Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: Customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic acids Res. 2021;49:D605–D612.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic acids Res. 2017;45:W98–W102.
Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic acids Res. 2019;47:W556–W560.
Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The cancer genome atlas Pan-Cancer analysis project. Nat Genet. 2013;45:1113–20.
Yu G, Wang LG, Han Y, He QY. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 2012;16:284–7.
Uhlen M, Zhang C, Lee S, Sjostedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357:eaan2507.
Acknowledgements
This work was supported by National Institutes of Health grant GM135547 and the research grants from OCAST and PHF to XAZ. XAZ is an Oklahoma TSET Cancer Research Scholar. We thank Ms. Kathy Kyler for English editing.
Author information
Authors and Affiliations
Contributions
YD, JXC, SL, JDW, and AKB performed analysis and wrote the manuscript; LL and XAZ supervised the study; XAZ conceived and designed the study; and YD, JXC, JDW, AKB, JW, TT, HCR, FAH, and XAZ wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ding, Y., Chen, J., Li, S. et al. EWI2 and its relatives in Tetraspanin-enriched membrane domains regulate malignancy. Oncogene 42, 861–868 (2023). https://doi.org/10.1038/s41388-023-02623-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41388-023-02623-8